News
Latest News
Safinamide significantly improves Quality of Life (QoL) in early and advan-ced Parkinson’s disease (PD) patients.
Safinamide filing for regulatory approval as add-on in early and mid-to late PD patients in EU and US expected in Q4/2013
Milan, Italy, April 22, 2013 – Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, pri-mary care and CNS therapeutic areas, presented results from Phase III studies with saf-inamide at the 9th International Congress on Mental Dysfunction & Other Non-Motor Features in Parkinson’s Disease and Related Disorders, on April 20, 2013.